William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and reach over $1 billion in global sales.

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...

Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in ...

The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025. CTX-10726 (a novel PD-1 x ...

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has ...